NCCN Updates NHL Guidelines to Incorporate FDA Approvals of New Treatment Options
Following the FDA approvals of two new therapies for Non-Hodgkin's Lymphomas (NHL), the NCCN Guidelines for NHL have been updated to include ofatumumab (Azerra™, GlaxoSmithKline) as a therapy option for patients with chronic lymphocytic leukemia (CLL) and romidepsin (Istodax®, Gloucester Pharmaceuticals) as a suggested treatment for patients with cutaneous T-cell lymphoma (CTCL).
November 23, 2009
FORT WASHINGTON, PA - Two recent FDA approvals have prompted the National Comprehensive Cance...
Source: National Comprehensive Cancer Network - Category: Cancer & Oncology Source Type: news
More News: Cancer | Cancer & Oncology | Chronic Leukemia | Chronic Lymphocytic Leukemia | Cutaneous T cell lymphoma | Leukemia | Lymphoma | T-cell Lymphoma